News Article
Nov 4, 2015
ReViral are delighted to announce the appointment of Dr Rachel Harland to the post of COO in the company’s management team

Dr Harland is a very experienced toxicologist with a wide range of development experience. She joins ReViral from Astra-Zeneca where she has been directing a wide range of toxicology programmes. In her career Rachel has taken many projects from the preclinical phase to full market authorization. Rachel has worked both for large pharmaceutical companies (Roche, Shire and SK) as well as having the role of Development Manager at Arrow Therapeutics.

In this new role Rachel will take responsibility for directing Reviral’s development process as well as the administration of the R&D process at company head office. Rachel’s experience of the business development process in the pharmaceutical industry including due diligence is a very valuable asset for the company.